Host Transcriptome Signatures for Mycoplasma Pneumonia Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Mycoplasma pneumoniae infections are unreliable, leading to delayed and inaccurate treatment decisions due to the complexity of obtaining direct microbiological samples, low sensitivity of cultures, and low specificity of serology tests, which complicates the differentiation from other bacterial or viral pneumonias and affects the choice of antibiotic treatment.
Innovation Solution
Development of predictive gene expression signatures using lasso regression simulation and blood microarray data to identify specific host-transcriptome patterns for Mycoplasma pneumoniae infection, enabling accurate differentiation from other pneumonias and guiding antibiotic treatment choices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct microbiological sampling methods are used for M. pneumoniae diagnosis, then diagnostic reliability can be improved, but the complexity of the procedure and invasiveness increase significantly
Solution Approach 1:
The patent uses host gene expression profiles as an intermediary marker to indirectly detect M. pneumoniae infection. Instead of directly sampling and culturing the pathogen (which is complex and invasive), the method measures the host's transcriptional response to the infection. This intermediary approach maintains diagnostic reliability while avoiding the complexities of direct microbiological sampling.
2Measurement precision
If culture methods are used for M. pneumoniae diagnosis, then diagnostic accuracy can be improved, but the time required for results increases due to slow growth
Solution Approach 1:
The method performs preliminary detection by measuring host gene expression changes that occur early in the infection process. Rather than waiting for M. pneumoniae to grow in culture (which takes time), the host's transcriptional response is detected immediately, providing rapid diagnostic results while maintaining accuracy.
3Ease of operation
If serology tests are used for M. pneumoniae diagnosis, then the procedure can be simplified, but specificity decreases due to cross-reactivity and persistent IgM positivity
Solution Approach 1:
Instead of measuring general immune responses (like total IgM) that lack specificity, the patent measures specific host gene expression patterns that are locally characteristic of M. pneumoniae infection. This approach maintains procedural simplicity while achieving high diagnostic specificity by focusing on infection-specific transcriptional signatures rather than general immune markers.
4Productivity
If empirical antibiotic treatment is initiated without specific diagnosis, then treatment can be started immediately, but inappropriate antibiotic selection occurs leading to treatment failure
Solution Approach 1:
The patent performs preliminary diagnostic assessment through host gene expression profiling before initiating antibiotic treatment. This allows clinicians to identify M. pneumoniae infection specifically and select appropriate antibiotics (macrolides) while avoiding ineffective treatments (beta-lactams), thus maintaining rapid treatment initiation while ensuring treatment appropriateness.
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
The present invention refers to an in vitro method for the diagnosis of a Mycoplasma pneumoniae infection and/or for the differential diagnosis between a Mycoplasma pneumoniae pneumonia and other bacterial or viral pneumonias and/or for assessing whether to treat a patient suffering from pneumonia with a macrolide antibiotic.